Form 4: Regulus Therapeutics CEO Acquires 990,000 Stock Options

Regulus Therapeutics' CEO, Joseph P. Hagan, was granted 990,000 stock options on May 20, 2024, according to a Form 4 filing with the SEC.

Summary

• Joseph P. Hagan, CEO of Regulus Therapeutics Inc., acquired 990,000 stock options on May 20, 2024.
• The options have an exercise price of $2.01.
• The options vest ratably on a monthly basis over 48 months, contingent upon continuous service to Regulus.
• The options expire on May 19, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to executive compensation. The grant of options is generally viewed as a positive, aligning management interests with shareholders, but it's not a major event.

Positives

• The CEO's acquisition of stock options aligns his interests with those of the shareholders, incentivizing him to improve the company's performance.

Industry Context

This is a standard practice for incentivizing executives in publicly traded companies. Stock options are a common form of compensation.

Comparison to Industry Standards

• Granting stock options to CEOs is a common practice in the biotechnology industry to align executive compensation with company performance.
• Comparable companies like Ionis Pharmaceuticals and Alnylam Pharmaceuticals also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

• The granting of stock options could potentially increase shareholder value if the CEO successfully executes the company's strategy and increases the stock price.

Key Dates